latest news releases from the newsroom
Transmeridian Exploration, Inc.
Transmeridian Exploration Reports Third Quarter 2006 Results of Operations
HOUSTON, Nov. 7, 2006 (PRIMEZONE) -- Transmeridian Exploration Incorporated (AMEX:TMY) reported a net loss of $14.3 million, or $0.15 per share, on net revenues of $7.8 million for the three months ended September 30, 2006, as compared to a net loss of $2.8 million, or $0.03 per share, on net revenues of $3.9 million for the three months ended September 30, 2005. For the nine months ended September 30, 2006, the net loss was $40.6 million, or $0.44 per share, on net revenues of $15.7 million, as compared to a net loss of $6.9 million, or $0.09 per share, on net revenues of $7.0 million for the nine months ended September 30, 2005.
WCA Waste Corporation
WCA to Add Independent Directors
HOUSTON, Nov. 7, 2006 (PRIMEZONE) -- WCA Waste Corporation (Nasdaq:WCAA) announced today that it has submitted a plan to NASDAQ for adding independent directors to its Board of Directors. Immediately after its Annual Meeting this year, Ares Corporate Opportunities Fund II, L.P. ("Ares") elected Mr. Antony P. Ressler and Mr. Jeffrey S. Serota to serve as members of the Board. Ares, as the sole owner of WCA's Series A Convertible Pay-In-Kind Preferred Stock, par value $0.01 per share, is entitled to elect members to the Board voting as separate class. On September 15, 2006, WCA provided notice to the Nasdaq Global Market ("Nasdaq") that after the election of Messrs. Ressler and Serota by Ares WCA no longer satisfied the independent director requirements for continued listing on Nasdaq under Marketplace Rule 4350(c)(1), which requires WCA to maintain a majority of independent directors on its Board.
Medicis Pharmaceutical Corporation
Medicis and Dow Pharmaceutical Sciences Announce FDA Approval of Ziana (Clindamycin Phosphate 1.2% and Tretinoin 0.025%) Gel
SCOTTSDALE, Ariz. and PETALUMA, Calif., Nov. 7, 2006 (PRIMEZONE) -- Medicis (NYSE:MRX) and Dow Pharmaceutical Sciences, Inc. ("Dow Pharmaceutical Sciences") today announced that the U.S. Food and Drug Administration ("FDA") has approved ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel. ZIANA(TM) Gel is the first and only combination of clindamycin and tretinoin approved for once daily use for the topical treatment of acne vulgaris in patients 12 years or older. ZIANA(TM) Gel is also the first and only approved acne product to combine an antibiotic and a retinoid. ZIANA(TM) Gel contains clindamycin phosphate 1.2% and tretinoin 0.025%, formulated as a cosmetically elegant topical gel. ZIANA(TM) Gel has an alcohol-free, aqueous base. Medicis expects product supply to be available for shipping to wholesalers in the fourth quarter of 2006, and anticipates promotion and sample distribution of ZIANA(TM) Gel to physicians shortly thereafter.